Simple But Effective
An Experimental Nanoparticle Covid-19 Test
Researchers reveal their experimental test can detect the presence of COVID-19 RNA in a sample in 10 minutes, and in a way that does not require trained personnel to interpret.
Coronavirus particles in grey on a red background
Scientists have developed a test for COVID-19 that can visually detect the presence of the coronavirus in 10 minutes. The team suggest their test, after further assessment, could be a rapid, inexpensive and more simple diagnostic strategy, compared to the laboratory alternatives.
A nasal swab containing a test sample is mixed with a simple lab test. It contains a liquid mixed with gold nanoparticles attached to a molecule that binds to the novel coronavirus. If the virus is present, the gold nanoparticles turns the solution a deep blue colour (bottom of the tube) and a precipitation is noticed. If it is not present, the solution retains its original purple colour.
A nasal swab containing a test sample is mixed with a simple lab test. It contains a liquid mixed with gold nanoparticles attached to a molecule that binds to the novel coronavirus. If the virus is present, the gold nanoparticles turns the solution a deep blue colour (bottom of the tube) and a precipitation is noticed. If it is not present, the solution retains its original purple colour.
The assay developed by University of Maryland School of Medicine (UMSOM), US, researchers analyses RNA samples extracted from a patient’s nasal swap or saliva sample, using a highly specific molecule attached to gold nanoparticles to detect viral RNA. If the viral protein is present in the sample, the molecule (acting as a biosensor) binds to it and the attached gold nanoparticle changes the colour of the liquid reagent from purple to blue – indicating COVID-19 proteins are present.
“Based on our preliminary results, we believe this promising new test may detect RNA material from the virus as early as the first day of infection. Additional studies are needed, however, to confirm whether this is indeed the case,” said study leader Dr Dipanjan Pan, Professor of Diagnostic Radiology and Nuclear Medicine and Paediatrics at the UMSOM.
Dr Pan also explained that “the accuracy of any COVID-19 test is based on being able to reliably detect any virus. This means it does not give a false negative result if the virus actually is present, nor a false positive result if the virus is not present. Many of the diagnostic tests currently on the market cannot detect the virus until several days after infection. For this reason, they have a significant rate of false negative results.”
He has now created a company, called VitruVian Bio, to develop the test for commercial application. Dr Pan also plans to have a pre-submission meeting with the US Food and Drug Administration (FDA) within the next month to discuss requirements for getting an emergency use authorisation for the test. However, new FDA policy allows the marketing of COVID-19 tests without requiring them to go through the usual approval processes, so long as they meet certain validation requirements.
Study co-author, Dr Matthew Frieman, Associate Professor of Microbiology and Immunology at UMSOM added: “This RNA-based test appears to be very promising in terms of detecting the virus. The innovative approach provides results without the need for a sophisticated laboratory facility.”
Developing a COVID-19 biosensor for faster diagnostics and environmental monitoring…
The team said that despite more clinical testing being required, what they developed could provide a cheaper and simpler alternative to the COVID-19 laboratory tests, able to be used by untrained personnel. The concluded that if it meets FDA expectations, the test could potentially be used as a surveillance technique to monitor any resurgence of infections in places like care homes and schools.
The paper was published in ACS Nano.
60,000 doses of avifavir
A Covid-19 Treatment To Be Delivered In June
The Russian Direct Investment Fund (RDIF) and the ChemRar Group are to deliver the doses of avifavir, approved in Russia as a COVID-19 therapeutic, to Russian hospitals.
coronavirus particles
Avifavir has received a registration certificate from the Ministry of Health of the Russian Federation, making it the first favipiravir-based drug approved for treating COVID-19.
The Russian Direct Investment Fund (RDIF) – Russia’s sovereign wealth fund – and the ChemRar Group have announced they will deliver 60,000 courses of avifavir to Russian hospitals in June.
Avifavir, originally developed to combat severe forms of influenza, demonstrated the ability to disrupt the reproductive mechanisms of COVID-19 in clinical trials. It has also been approved for use against influenza in Japan since 2014, so its safety is well established and studied.
Watch the latest on-demand webinar on ‘A 360 overview of data Integrity in life sciences’ supported by OSIsoft
Our one-hour session covers why the trustworthiness in data is critical for operations within the pharmaceutical and life sciences industries, whether it is for compliance, operational excellence, reporting or development.
WATCH NOW
The intermediate data from the avifavir clinical trials suggest it has high efficacy against COVID-19:
After 10 days of trials, the median time to eliminate COVID-19 with the avifavir was four days, compared to nine with standard therapy
After four days 65 percent of avifavir recipients tested negative for COVID-19, by 10 days this number had increased to 90 percent
